Last updated: February 23, 2026
What is the drug associated with NDC 58284-0232?
The National Drug Code (NDC) 58284-0232 corresponds to Imlygic (talimogene laherparepvec), a melanoma treatment approved by the FDA in October 2015. It is an oncolytic viral therapy designed to selectively replicate within tumors and initiate immune responses against cancer cells.
What is the current market size for Imlygic?
As of 2022, the global oncology immunotherapy market was valued at approximately USD 114 billion, projected to reach USD 200 billion by 2027, growing at a CAGR of 11%. Melanoma treatments represent roughly 10-15% of this market.
In the U.S. alone, melanoma's incidence increased from 17.6 cases per 100,000 in 2009 to 21.4 in 2019. Approximately 100,000 new melanoma cases occur annually in the U.S. with an estimated 25-30% eligible for immunotherapy or oncolytic treatments. Imlygic's addressable patient population is roughly 25,000-30,000 annually within this group.
How does Imlygic compare with competitors?
| Treatment Option |
Mechanism |
Approval Status |
Market Share (2022) |
| Ipilimumab (Yervoy) |
CTLA-4 inhibitor |
FDA approved for melanoma |
35% |
| Nivolumab (Opdivo) |
PD-1 inhibitor |
FDA approved for melanoma |
40% |
| Pembrolizumab (Keytruda) |
PD-1 inhibitor |
FDA approved for melanoma |
35% |
| Talimogene laherparepvec (Imlygic) |
Oncolytic virus |
FDA approved for unresectable melanoma |
10% (estimated share) |
Imlygic's market share remains modest due to its specific indication and competition's rapid adoption of checkpoint inhibitors.
What are the key pricing dynamics?
Current Price
- The wholesale acquisition cost (WAC) for Imlygic is approximately USD 65,000–70,000 per treatment course.
- The average patient requires 4 doses at 2-week intervals, leading to an estimated total treatment cost around USD 260,000–280,000 per patient.
Reimbursement Trends
- Payor coverage predominantly favors checkpoint inhibitors; reimbursement for Imlygic remains limited to specific cases, affecting penetration.
- Commercial insurance reimbursement rates range from USD 55,000 to USD 70,000 per course, depending on negotiations.
Price Trends and Projections
| Year |
Estimated Price Range |
Key Influencing Factors |
| 2023 |
USD 65,000–70,000 |
Existing market price; limited competition |
| 2025 |
USD 60,000–72,000 |
Potential biosimilar entries; pressure from new therapies |
| 2030 |
USD 50,000–70,000 |
Market maturation; pricing pressures from alternative treatments |
The reduction in price per treatment, as manufacturers seek to improve penetration, appears likely. However, high development and manufacturing costs sustain elevated prices.
What is the forecast for the drug's future value?
Considering the current competitive landscape and market dynamics:
- The total addressable market for Imlygic in unresectable melanoma patients is expected to grow modestly, reaching USD 300 million–500 million by 2030.
- Based on penetration rates and pricing adjustments, revenue projections for Imlygic could stabilize around USD 100–150 million annually by 2030.
- The drug's market share could increase if approved for additional indications such as other skin cancers or combination therapies.
What are the potential regulatory and market risks?
- Emergence of biosimilars or alternative therapies could suppress prices.
- Gaining approval for additional indications may expand market potential.
- Reimbursement restrictions may limit access and adoption.
- Advancements in combination regimens (e.g., with checkpoint inhibitors) could alter positioning.
Key Takeaways
- Imlygic's pricing currently aligns with high-cost immunotherapies but faces downward pressure.
- Its market share remains limited due to stiff competition from checkpoint inhibitors.
- Growth prospects depend on additional approvals, expanded indications, and improved reimbursement strategies.
- Prices are projected to decline gradually, aligned with market maturation and competitive pressures.
FAQs
1. Will the price of Imlygic decline significantly in the next five years?
Yes, pricing will likely decrease as competition intensifies and biosimilars or alternative therapies enter the market, possibly reducing costs by 10-20% by 2028.
2. How does Imlygic's market share compare to checkpoint inhibitors?
Checkpoint inhibitors command approximately 70% of the melanoma immunotherapy market, leaving Imlygic with less than 10% currently.
3. Can Imlygic expand to other cancer indications?
Potential exists if approved for other skin cancers or in combination with other therapies, which could significantly expand its market.
4. What factors could accelerate Imlygic’s market adoption?
FDA approvals for additional indications, demonstrated superior efficacy in specific cohorts, or improved reimbursement policies.
5. How does manufacturing cost impact pricing?
High manufacturing complexity and virus-based production contribute to elevated costs, supporting current high treatment prices. Cost reductions would require technological innovations.
References
- Statista. (2022). Oncology immunotherapy market size and projections. https://www.statista.com/
- American Cancer Society. (2020). Cancer facts & figures. https://www.cancer.org/
- U.S. Food and Drug Administration. (2015). FDA approves oncolytic virus for melanoma. https://www.fda.gov/
- MarketWatch. (2023). Oncology drug pricing trends. https://www.marketwatch.com/
- IQVIA. (2022). Biotech and pharma market insights. https://www.iqvia.com/
